Red Light Holland adds certificate of analysis

Executive Summary

• Red Light Holland Corp. received an official Certificate of Analysis (COA) from its FDA‑compliant, DEA‑registered partner Irvine Labs confirming psilocybin potency and process validation for potential medical‑grade manufacturing.
• The COA was based on testing of naturally derived psilocybin truffles shipped from the Netherlands to Irvine Labs in California, demonstrating compatibility with upcoming manufacturing processes.
• The company is preparing a larger psilocybin export in 2025 under Irvine Labs’ existing DEA quota, advancing its strategy to develop standardized medical‑grade psilocybin products for therapeutic markets and clinical trials.

Key Details

• Certificate of Analysis (COA): Issued by Irvine Labs Inc., confirming potency levels and process validation for Red Light Holland’s psilocybin truffles.
• Testing Scope: Conducted on naturally derived psilocybin truffles produced at Red Light Holland’s Netherlands facility and shipped to Irvine Labs’ FDA‑compliant, DEA‑registered laboratory in California.
• Manufacturing Compatibility: Results indicate the material meets specifications for integration into medical‑grade manufacturing processes being developed by the partnership.
• Dehydration & Packaging Advances: Ongoing proprietary dehydration and packaging methods aim to extend shelf life while preserving product integrity.
• Future Export Plans: Red Light Holland is preparing a larger psilocybin export in 2025, utilizing Irvine Labs’ existing DEA quota allocation for that year.
• Strategic Goal: Development of standardized psilocybin products targeting emerging therapeutic markets, government‑funded pilot programs, and clinical trials.

Notable Quotes

(No direct quotes were provided in the release.)